Abstract
Moxonidine and related compounds have been recently introduced into antihypertensive therapy. It is thought that these drugs exert their blood pressure lowering effect through interaction with nonadrenergic receptors in the central nervous system, i.e. imidazoline receptors, although the contribution of specific interaction with α2-receptors is still under debate. Imidazoline receptors have recently been documented in the renal proximal tubule. In experimental studies, interaction of imidazolines with these receptors decreased the activity of the Na+/H+ antiporter and induced natriuresis. To quantitate the effect of the imidazoline receptor agonist moxonidine on renal sodium handling and renal haemodynamics in man, we examined ten healthy normotensive males (aged 25 ± 4 years) in a double blind placebo-controlled study using a crossover design. Subjects were studied on a standardized salt intake (50 mmol per day). On the 7th and 10th study day they were randomly allocated to receive either i.v. placebo or i.v. 0.2 mg moxonidine. Urinary electrolyte excretion, lithium clearance (as an index of proximal tubular sodium handling), glomerular filtration rate (GFR), effective renal plasma flow (ERPF), renal vascular resistance (RVR), mean arterial blood pressure (MAP), plasma renin activity (PRA) and plasma noradrenaline (NA) levels were assessed. Injection of moxonidine did not increase fractional sodium excretion or lithium clearance. Specifically, antinatriuresis was not observed after injection of moxonidine despite a significant decrease in MAP from 91 to 85 mmHg and a significant increase in PRA. MAP and PRA did not change with administration of placebo. Injection of moxonidine did not affect GFR and RVR; ERPF decreased slightly but not significantly. Acute administration of 0.2 mg i.v. moxonidine decreased blood pressure in healthy volunteers on standardized salt intake, but did not affect natriuresis, proximal tubular sodium reabsorption or glomerular filtration rate. The absence of an antinatriuretic response despite a decrease in blood pressure suggests a direct facilitation of natriuresis by moxonidine.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Bousquet P, Feldman J, Schwartz J (1984) Central cardiovascular effects of alpha adrenergic drugs. Differences between catecholamines and imidazolines. J Pharmacol Exp Ther 230:232–238
Haxhiu MA, Dreshaj I, Erokwu B, Schäfer SG, Christen MO, Ernsberger PR (1992) Vasodepression elicited in hypertensive rats by the selective I1-imidazoline agonist moxonidine administered into the rostral ventrolateral medulla. J Cardiovasc Pharmacol 20 [Suppl 4]:S11-S15
Ernsberger P, Giuliano R, Willette RN, Reis DJ (1990) Role of imidazole receptors in the vasodepressor response to clonidine analogues in the rostral ventrolateral medulla. J Pharmacol Exp Ther 253:408–418
Feldman J, Tibirica E, Bricca G, Dontenwill M, Belcourt A, Bousquet P (1990) Evidence for the involvement of imidazoline receptors in the central hypotensive effect of rilmenidine in the rabbit. Br J Pharmacol 100:600–607
Gomez R, Ernsberger P, Feinland G, Reis DJ (1991) Rilmenidine lowers arterial pressure via imidazoline receptors in brainstem C1 area. Eur J Pharmacol 195:181–191
Schlicker E, Armah BI, Göthert M (1990) Central presynaptic α2-autoreceptors are involved in the blood pressure-lowering effect of moxonidine. J Cardiovasc Pharmacol 16:15–22
Plänitz V (1987) Comparison of moxonidine and clonidine HCl in treating patients with hypertension. J Clin Pharmacol 27:46–51
Udvary E, Schäfer SG, Vegh A, Szekeres L (1990) Hemodynamic effects of a new centrally acting antihypertensive agent moxonidine as compared to clonidine. Eur J Pharmacol 183:2064–2069
Plänitz V (1986) Intraindividual comparison of moxonodine and prazosin in hypertensive patients. Eur J Clin Pharmacol 1986; 29:645–650
Prichard BNC, Simmons R, Rooks MJ, Haworth DA, Laws D (1992) A double-blind comparison of moxonidine and atenolol in the management of patients with mild to moderate hypertension. J Cardiovasc Pharmacol 20 [Suppl]:S45-S49
Wolf R (1992) The treatment of hypertensive patients with a calcium antagonist or moxonidine: a comparison. J Cardiovasc Pharmacol 20 [Suppl]:S42-S44
De Sarro GB, Ascioti C, Froio F, Libri V, Nistico G (1987) Evidence that locus coeruleus is the site where clonidine and drugs acting at α1-and α2-adrenoreceptors affect sleep and arousal mechanisms. Br J Pharmacol 90:675–680
Lachaud-Pettiti V, Podevin RA, Chretien Y, Parini A (1991) Imidazoline-guanidinium and α2-adrenergic binding sites in basolateral membranes from human kidney. Eur J Pharmacol 206:23–31
Lachaud V, Limon I, Tesson F, Coupry I, Parini A (1992) Characterization of imidazoline-guanidinium receptive sites in renal medulla from human kidney. Am J Hypertens 5 [Suppl]:69S-71S
Nord EP, Howard NJ, Hafezi P, Moradeshagi P Vaystub S, Isel PA (1987) A2-adrenergic agonists stimulate Na+/H+ antiporter activity in the rabbit proximal tubule. J Clin Invest 80:1755–1762
Gesek FA, Strandhoy JW (1990) Dual interaction between α2-adrenoreceptor agonists and the proximal Na+/H+ exchanger. Am J Physiol 258:F636-F642
Bidet M, Pujeol P, Parini A (1990) Effect of imidazolines on Na+ transport and intracellular pH in renal proximal tubule cells. Biochim Biophys Acta 1024:173–178
Allan DR, Penner SB, Smyth DD (1993) Renal imidazoline preferring sites and solute excretion in the rat. Br J Pharmacol 108:870–876
Weicker H (1988) Determination of free and sulfoconjugated catecholamines in plasma and urine by HPLC. Int J Sports Med 9:225–233
Kühnle HF, von Dahl K, Schmidt F (1992) Fully enzymatic inulin determination in small volume samples without deproteination. Nephron 62:104–107
Bratton AC, Marshall EK (1938) A new coupling component for sulfanilamide determination. J Biol Chem 128:537–550
Thomsen K (1984) Lithium clearance: a new method for determining proximal and distal tubular reabsorption of sodium and water. Nephron 37:217–223
DiBona GF (1989) Neural control of renal function: cardiovascular implications. Hypertension 13:539–548
Frisk-Holmberg M, Plänitz V (1987) A selective α-adrenoreceptor agonist in essential arterial hypertension. Cur Ther Res 42 [Suppl 1]:138–146
Grabbie M, Nussbaum P, Goldfarb S (1980) Effects of Methyldopa on renal hemodynamics and tubular function. Clin Pharmacol Ther 27:522–527
Goldberg M, Gehr M (1985) Effects of α-2 agonists on renal function in hypertensive humans. J Cardiovasc Pharmacol 7 [Suppl 8]:S34-S37
Mitrovic V, Patyna W, Hüting J, Schlepper M (1991) Hemodynamic and neurohumoral effects of moxonidine in patients with essential hypertension. Cardiovasc Drug Ther 5:967–972
Fliser D, Fode P, Arnold U, Kohl B, Novicki M, Ritz E (1995) The effect of dietary salt on insulin sensitivity. Eur J Clin Invest 25:39–43
Chrisp P, Faulds D (1992) Moxonidine. A review of its pharmacology, and therapeutic use in essential hypertension. Drugs 44:993–1012
Theodor R, Weimann HJ, Weber W, Michaelis K (1991) Absolute bioavailability of moxonidine. Eur J Drug Metab Pharmacokinet 16:153–159
Frei M, Küster L, Gardosch H, Krosigk PP von, Koch HF, Küppers H (1994) Moxonidine and hydrochlorothiazide in combination: a synergistic antihypertensive effect. J Cardiovasc Pharmacol 24 [Suppl 1]:S25-S28
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Wiecek, A., Nowicki, M., Fliser, D. et al. Effect of moxonidine on urinary electrolyte excretion and renal haemodynamics in man. Eur J Clin Pharmacol 48, 203–208 (1995). https://doi.org/10.1007/BF00198299
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00198299